Browsing Category
Pharma Industry News
4722 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Novo Nordisk gets UK nod for single-dose Wegovy 7.2mg pen in obesity care
MHRA has approved the single-dose Wegovy 7.2mg pen for adults with obesity in the United Kingdom. Read what it means for patients and Novo Nordisk.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Kazia Therapeutics (NASDAQ: KZIA) bets on SETDB1 to widen oncology pipeline beyond paxalisib
Kazia Therapeutics has licensed a SETDB1 oncology platform from QIMR Berghofer. Read why the move could reshape KZIA’s pipeline strategy.
Hoth Therapeutics stock jumps on HT-VA data, but can HOTH turn preclinical promise into a real metabolic pipeline?
Hoth Therapeutics says HT-VA reprogrammed liver fat metabolism and outperformed semaglutide on key markers. Read what this means for HOTH now.
Who is really leading Indian pharma in 2026? The top 10 companies explained beyond the hype
Discover the top 10 pharma companies in India in 2026, who leads by revenue, reach, and strategy, and why the ranking is more complex than it looks.
Could intratumoral peptide immunotherapy alter first-line thinking in basal cell carcinoma?
Could VP-315 reshape first-line basal cell carcinoma treatment? Read the executive analysis on strategy, competition, and commercial risks.
Could Pixclara become the missing imaging tool in U.S. glioma care after FDA NDA acceptance?
Could Pixclara transform U.S. glioma imaging after FDA NDA acceptance? Explore what Telix Pharmaceuticals Limited’s September catalyst could change next.
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
Could Neurocrine’s $2.9bn Soleno deal turn VYKAT XR into its next rare-disease blockbuster?
Neurocrine is buying Soleno for $2.9 billion to add VYKAT XR. Read what the deal means for NBIX growth, rare-disease strategy, and investor sentiment.
Gilead Sciences (GILD) is buying Tubulis after Arcellx and Ouro. How aggressive is this deal spree getting?
Gilead is acquiring Tubulis for up to $5 billion to expand its ADC pipeline. Read what the deal means for oncology strategy, risk, and GILD stock.